CDH26

Across TCGA pan-cancer cohorts, CDH26 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated CDH26 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CDH26 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDH26 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

OV, UCS, and UCEC are the cancer types where CDH26 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.291	0.692	.022	36	view →
UCS	OS	Median	All	0.144	0.698	<.001	36	view →
UCEC	DFS	Median	II,III,IV	1.000	0.298	.001	36	view →
CESC	OS	Median	All	0.483	0.800	.002	30	view →
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	12	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
BLCA	OS	Median	II,III,IV	0.866	0.409	.035	6	view →
PRAD	DFS	Median	All	0.617	0.886	.027	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
SKCM	OS	Median	III,IV	0.320	0.729	.024	6	view →
STAD	OS	Median	IV	0.111	0.433	.002	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

CDH26–OV (OS)

Open the OV breakdown →